Bill Text

Bill Information


Bill PDF |Add To My Favorites | print page

SB-1442 Point-of-care tests for fentanyl.(2023-2024)

SHARE THIS: share this bill in Facebook share this bill in Twitter
Date Published: 06/13/2024 09:00 PM
SB1442:v96#DOCUMENT

Amended  IN  Assembly  June 13, 2024
Amended  IN  Senate  May 16, 2024
Amended  IN  Senate  March 18, 2024

CALIFORNIA LEGISLATURE— 2023–2024 REGULAR SESSION

Senate Bill
No. 1442


Introduced by Senators Ochoa Bogh and Skinner
(Coauthor: Senator McGuire)(Coauthors: Senators Becker, McGuire, and Rubio)

February 16, 2024


An act to add Section 127697.1 to the Health and Safety Code, relating to public health.


LEGISLATIVE COUNSEL'S DIGEST


SB 1442, as amended, Ochoa Bogh. Point-of-care tests for fentanyl.
Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) to enter into partnerships, in consultation with other state departments as necessary, to, among other things, increase patient access to affordable drugs. Existing law authorizes CHHSA to enter into partnerships regarding over-the-counter naloxone products for the development, manufacturing, or distribution of those products, as specified.
This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law.
Vote: MAJORITY   Appropriation: NO   Fiscal Committee: YES   Local Program: NO  

The people of the State of California do enact as follows:


SECTION 1.

 Section 127697.1 is added to the Health and Safety Code, to read:

127697.1.
 (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law.
(b) For purposes of this section, “point-of-care test for fentanyl” means a point-of-care test for use by a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine.